Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesMedulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09
Conroy S et al. – The pre–determined criteria were not applicable, in their entirety, in the majority of drugs, due to lack of information in the academic domain, emphasising the importance of a more open approach for sharing basic drug information. The prioritised list of 12 candidate drugs for clinical trial and 15 for pre–clinical investigation justify that a concerted research effort in this area of practice is made.
David Walker, 10/29/09
| This work was stimulated by the observation of the considerable brain and skeletal injury,currently suffered by young children treated by cranio spinal radiotherapy for medulloblastoma. The efficacy of systemic chemotherapy is limited by systemic toxicity and drug access to the central nervous system. Intrathecal chemotherapy has been used successfully in medulloblastoma and in ALL producing the excellent control of CNS disease. We decided to review established chemotherapy agents for efficacy against medulloblastoma and suitability for intrathecal administration. The systematic literature review identified a major gap in the availability of information about pharmacological characteristics of established drugs whilst also testing criteria for drug selection and then applying these where possible, and where not, using whatever information that was avaialble to select and rank drugs for future testing in this clinical condition. This review will stimulate debate regarding drug selection and promote a renewed interest in the use of this route of drug administration. It would be a remarkable response if Pharma and Academia agreed to share basic pharmacological information about their new and old cancer drugs in a systematic and open fashion. |
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
BMC Cancer, 10/22/09
Reirradiation for progressive brain metastases
Journal of Cancer Research and Therapeutics, 10/27/09
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
Sponsor
Article Search
Sponsor